Stay updated on Pembrolizumab in Hypermutation Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.

Latest updates to the Pembrolizumab in Hypermutation Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision: v3.4.2 was added to the page. The government funding lapse notice and the v3.4.1 revision information were removed.SummaryDifference0.4%

- Check23 days agoChange DetectedAdded a government funding lapse notice at the top of the page and updated the site version to v3.4.1, replacing v3.4.0; these are administrative UI changes that do not affect study details, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check30 days agoChange DetectedThe page now shows 'Results Submitted' and 'Last Update Submitted that Met QC Criteria', along with a new site revision (v3.4.0). The previous indicators like 'No Results Posted' and related status text have been removed.SummaryDifference0.3%

- Check45 days agoChange DetectedThe page shows a revision update from v3.3.3 to v3.3.4; no substantive updates to the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page footer now shows Revision: v3.3.3, and the previous Revision: v3.3.2 and the HHS Vulnerability Disclosure text have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check95 days agoChange DetectedThe changes update the Publications section wording to indicate that PubMed-listed publications are automatically populated from PubMed, and note the revision version. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Hypermutation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.